進行非小細胞癌化学療法で，カルボプラチンはシスプラチンと同等の効果があるか

DOI Web Site 参考文献42件

書誌事項

タイトル別名
  • Meta-analysis About Cisplatin Versus Carboplatin in Advanced Non-small Cell Lung Cancer.

この論文をさがす

説明

Cisplatin based chemotherapy prolog the survival of good performance status patients with advanced non-small cell lung cancer, and improve the quality of life. Recently, Key drug for non-small cell lung cancer is shifting to carboplatin, based on the difference of toxicities. In this study cisplatin based chemotherapy were compared to carboplatin based chemotherapy in meta-analysis about tumor response and 1 year survival rate, in the randomized trials for non-small cell lung cancer. In the analysis on 8 randomized trials comparing cisplatin to carboplatin with same combination drugs, response rate was statistically significantly better in cisplatin base therapy than carboplatin. One year survival rate of Cisplatin and Carboplatin based therapy was 38.9% and 36.8% respectively. In the analysis on 6 randomized studies comparing cisplatin to carboplatin with newer agents combination therapy, response rate and one year survival rate were no significantly differences. One year survival rate of cisplatin and carboplatin based therapy were 37.7% and 36.8% respectively. In the chemotherapy for advanced non-small cell lung cancer, it is reasonable to choose the carboplatin as a key drug for combination therapy with newer agents.

収録刊行物

  • 肺癌

    肺癌 42 (7), 789-795, 2002

    特定非営利活動法人 日本肺癌学会

参考文献 (42)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ